Assessment of effectiveness of neoadjuvant chemotherapy in patients with resectable gastric cancer.

Abstract

e16006 Background: Despite a sharp decrease in gastric cancer (GC) incidence, it remains one of the most common cancers in Ukraine as well as the whole world. According to big data from randomized trials that was analyzed, neoadjuvant chemotherapy (CT) was one of the most effective options. This study was performed to assess the effectiveness and safety of neoadjuvant chemotherapy among patients with resectable gastric cancer. Methods: 73 patients with resectable gastric cancers were randomized in two groups: group A (n = 38) who underwent neoadjuvant chemotherapy (with FLOT scheme) followed by planned surgery and group B (n = 35) for whom only surgery was performed. Data was collected in the clinic of National Cancer Institute from 2011 to 2017. Primary endpoints were overall survival (OS), progression free survival (PFS) and biological marker evaluation. Results: Molecular marked VEGFR-1 was found to correlate with cancer tumor cells sensitivity to chemotherapy. There was no significant difference in 5-year OS (55.2% in group A and 57.1% in group B respectively, p = 0.18). There was also no significant difference in PFS between two groups (32.6 month vs 33.1 month respectively). Conclusions: this study showed that there is no significant difference for OS and PFS in patients with resectable gastric cancer whether they received neoadjuvant CT or not. But it was found that there molecular markers such as VEGFR-1 could be used as a predictors for tumor response on systemic treatment. Determination of sensitivity to neoadjuvant CT helps to avoid useless toxicity and offers reducing the overall cost of treatment.